AI Science Tracker

Centre for Medical Research, Ningbo No. 2 Hospital

1 discovery from 2024

Discoveries

Machine learning prioritizes 1-methylnicotinamide as a serum signal across HBV cirrhosis-to-HCC progression

Untargeted serum metabolomics from 69 participants, including eight patients followed from HBV-related cirrhosis to hepatocellular carcinoma (HCC), was analyzed with LASSO and random forest to prioritize metabolites. 1-methylnicotinamide (1-MNAM) declined across healthy, cirrhosis and HCC groups and was lower at the HCC than cirrhosis stage in the eight progressors. Targeted mass spectrometry in a separate cohort of 25 healthy controls and 25 early-stage HCC patients confirmed lower 1-MNAM in HCC (AUC 0.954 for HCC versus healthy controls).

Technology: LASSO regression and random forest classifier applied to serum metabolomics

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Targeted mass spectrometry in a separate cohort of 25 healthy controls and 25 early-stage HCC patients confirmed lower 1-MNAM in HCC (AUC 0.954 for HCC versus healthy controls).
  • Still unknown: The longitudinal transition signal comes from eight HBV-cirrhosis patients who progressed during follow-up. The independent targeted cohort compared 25 early-HCC patients with 25 healthy controls; it did not validate prediction of progression among cirrhosis patients. The authors describe the overall sample as small and call for larger prospective validation. 1-MNAM is a known endogenous metabolite; this record concerns the study-specific association and selection result, not discovery of a new compound, causal mechanism, or clinical test.
  • AI role: The authors used LASSO and random forest to select ten candidate metabolites distinguishing cirrhosis from HCC, then identified 1-MNAM as the sole candidate with a consistent decline across healthy, cirrhosis and HCC groups. The algorithms prioritized the measured metabolite; targeted mass spectrometry in a separate cohort provided assay follow-up.

Evidence sources: https://link.springer.com/article/10.1007/s00432-024-05848-6

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 63 of works of the same type, year and subfield (OpenAlex work metrics, 7 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.